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Rationale: Antibiotic treatment of patients infected with G− or G+ bacteria promotes
release of the toxins lipopolysaccharide (LPS) and pneumolysin (PLY) in their lungs. Growth
Hormone-releasing Hormone (GHRH) agonist JI-34 protects human lung microvascular
endothelial cells (HL-MVEC), expressing splice variant 1 (SV-1) of the receptor, from
PLY-induced barrier dysfunction. We investigated whether JI-34 also blunts LPS-induced
hyperpermeability. Since GHRH receptor (GHRH-R) signaling can potentially stimulate both
cAMP-dependent barrier-protective pathways as well as barrier-disruptive protein kinase C
pathways, we studied their interaction in GHRH agonist-treated HL-MVEC, in the presence
of PLY, by means of siRNA-mediated protein kinase A (PKA) depletion.
Methods: Barrier function measurements were done in HL-MVEC monolayers using
Electrical Cell substrate Impedance Sensing (ECIS) and VE-cadherin expression by
Western blotting. Capillary leak was assessed by Evans Blue dye (EBD) incorporation.
Cytokine generation in broncho-alveolar lavage fluid (BALF) was measured by multiplex
analysis. PKA and PKC-α activity were assessed by Western blotting.
Results: GHRH agonist JI-34 significantly blunts LPS-induced barrier dysfunction, at least
in part by preserving VE-cadherin expression, while not affecting inflammation. In addition
to activating PKA, GHRH agonist also increases PKC-α activity in PLY-treated HL-MVEC.
Treatment with PLY significantly decreases resistance in control siRNA-treated HL-MVEC,
but does so even more in PKA-depleted monolayers. Pretreatment with GHRH agonist
blunts PLY-induced permeability in control siRNA-treated HL-MVEC, but fails to improve
barrier function in PKA-depleted PLY-treated monolayers.
Conclusions: GHRH signaling in HL-MVEC protects from both LPS and PLY-mediated
endothelial barrier dysfunction and concurrently induces a barrier-protective PKA-mediated
and a barrier-disruptive PKC-α-induced pathway in the presence of PLY, the former of which
dominates the latter.
Keywords: capillary leak, pneumolysin, lipopolysaccharide, growth hormone-releasing hormone, protein kinase A,
protein kinase C
INTRODUCTION
Of the approximately 9 million children aged less than 5 years
that die each year worldwide, 1.6 million succumb from pneumo-
nia (Rudan et al., 2008). Indeed, pneumonia kills more children
world-wide than any other single illness. In the US more than
5 million cases of community-acquired pneumonia (CAP) are
diagnosed annually, mainly in the elderly population, with 7%
of them fatal (Waterer et al., 2011). Despite the widespread use
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of antibiotics, mortality during the first several days of pneu-
monia has not decreased appreciably over the past 75 years
(Evans and Gaisford, 1938; Waterer et al., 2011). Even though
the lungs are essentially free of bacteria following antibiotic
treatment, many patients still die from complications, the most
important one of which is pulmonary permeability edema. One
of the main causes of pneumonia-associated permeability edema
in patients treated with antibiotics is the massive release of
toxins, including pneumolysin (PLY), a virulence factor from
G+ pneumococci and lipopolysaccharide (LPS), an endotoxin
from G− bacteria (Anderson et al., 2007), following bacte-
rial lysis. Although inducing very different pathways leading to
endothelial dysfunction, both toxins are important mediators
of pneumonia-associated capillary leak, which is an important
problem contributing to permeability edema.
Endothelial and epithelial barrier functions are regulated by a
tight balance between opposing centripetal and centrifugal intra-
cellular forces, provided by the contractile machinery and the
elements opposing contraction, respectively. The elements oppos-
ing barrier dysfunction include tethering complexes, involved in
cell-cell and cell-matrix contacts, and systems that impart cell
rigidity and prevent cellular collapse, such as actin filaments,
microtubules, and intermediate filaments (Dudek and Garcia,
2001; Lucas et al., 2009).
The 53 kDa cytoplasmic cholesterol-binding and pore-
forming cytolysin, PLY, is a major pneumococcal virulence fac-
tor, and exerts its barrier-disruptive effects mainly through its
direct activities on myosin light chains (MLC) and on micro-
tubules (Rubins et al., 1996; Witzenrath et al., 2006; Lucas et al.,
2012a,b, 2013), rather than through stimulation of leukocyte
infiltration and cytokine generation (Maus et al., 2004). By con-
trast, the G− endotoxin, LPS, upon stimulation of TLR4 (Beutler
and Moresco, 2008), directly affects endothelial barrier function,
by means of a mechanism involving RhoA GTPase activation-
dependent downregulation of expression of the adherens junction
protein, VE-cadherin (Schlegel et al., 2009; Rafikov et al., 2014).
LPS-induced endothelial barrier dysfunction can be blunted by
cAMP-dependent activation of protein kinase A (PKA) (Csortos
et al., 2008; Bogatcheva et al., 2009; Umapathy et al., 2010). In
contrast to PLY, LPS also indirectly promotes hyperpermeability,
by means of potently activating leukocyte infiltration, inducing
oxidative and nitrosative stress. In addition, increased gener-
ation of pro-inflammatory cytokines (Umapathy et al., 2012;
Aggarwal et al., 2014; Gonzales et al., 2014), such as TNF, dramat-
ically affects microtubule arrangement in the lung endothelium
(Petrache et al., 2003). Currently, no standard treatment exists
to counteract LPS- or PLY-mediated permeability edema. As
such, the search for novel protective substances which can blunt
endothelial barrier dysfunction induced by these bacterial toxins
is of high clinical importance.
Generated in the posterior hypothalamus, the nominative
function of the Growth Hormone Releasing Hormone (GHRH) is
the stimulation of Growth Hormone production by the pituitary,
which expresses full length GHRH receptors (GHRH-R) (Mayo
et al., 1995; Sherwood et al., 2000). We have previously shown
that mRNA for the ligand GHRH and its bioactive receptor
splice variant, SV1, are also expressed in peripheral tissues, such
as in lung microvascular endothelial cells, pancreatic islets, and
cardiomyocytes (Rekasi et al., 2000; Kanashiro-Takeuchi et al.,
2010; Kiaris et al., 2011; Ludwig et al., 2012).
The 29 N-terminal amino acid residues of the GHRH sequence
possess full biological activity and thus constitute the core peptide
for the development of agonists of GHRH, such as JI-34, JI-36,
and JI-38, which are up to 80 times more potent than GHRH
(Izdebski et al., 1995; Cai et al., 2014). JI-34 was shown to pro-
tect from PLY-induced barrier dysfunction in vitro and in vivo,
in a cAMP-dependent manner (Lucas et al., 2012a). However, the
outcome of GHRH agonist treatment on LPS-induced hyperper-
meability in capillary endothelial cells in vitro and in vivo has not
been investigated.
Ligand or agonist binding to the GHRH-R changes recep-
tor conformation and activates the closely associated het-
erotrimeric Gs-protein. Upon this activation, the dissociated
Gαs subunit directly stimulates adenylate cyclase and intracel-
lular cAMP generation, which in turn activates PKA (Moretti
et al., 2002). However, GHRH belongs to the glucagon/secretin
superfamily that has been demonstrated to activate recep-
tors coupled with multiple heterotrimeric G proteins, partic-
ularly Gs and Gq (Moretti et al., 2002; Lania et al., 2003).
Therefore, in addition to cAMP accumulation and PKA activa-
tion via Gs, these receptors may also potentially induce a rise
in intracellular Ca2+ and PKC activation via Gq (Lania et al.,
2003).
The main aims of this study were to investigate whether apart
from PLY, GHRH agonists can also protect from LPS-induced
barrier dysfunction. We also investigated whether GHRH ago-
nists are able to activate both PKA-mediated barrier-protective
and PKC-mediated barrier-disruptive pathways in human lung
microvascular endothelial cells (HL-MVEC) and how these
pathways interact.
MATERIALS AND METHODS
CELLS
Human lung microvascular endothelial cells (HL-MVEC) and
human pulmonary artery endothelial cells (HPAEC) (Lonza,
Walkersville, MD, USA) were grown in complete EBM-2 medium
(Lonza, Walkersville, MD, USA) and used up to passage six.
Experiments with PLY were performed in serum-free medium,
whereas experiments with LPS were performed in medium con-
taining 5% FBS.
MICE
Eight to ten weeks old male C57BL6 mice, weighing 19–21 g
were obtained from Harlan and were kept at the animal facili-
ties at Georgia Regents University. All animal studies conformed
to National Institutes of Health guidelines. The experimen-
tal procedure was approved by the Georgia Regents University
Institutional Animal Care and Use Committee.
PLY PURIFICATION
PLY was purified from a recombinant Listeria innocua 6a strain
expressing LPS-free PLY in the laboratory of T.C. The batch
of PLY used in this study had a specific activity of 1.25 × 107
hemolytic units/mg.
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BIOCHEMICALS
Rabbit polyclonal anti–human vascular endothelial
(VE)-cadherin antibodies, anti-human PKA, anti-human
phospho-PKA, anti-human PKA substrate, anti-human PKC
substrate, and anti-human PKC-α were from Cell Signaling
Technology (Danvers, MA, USA). Rabbit anti-human phospho
PKC-α(Ser 657) was from Santa Cruz Biotechnology (Dallas, TX,
USA). Secondary goat anti-rabbit Texas Red-conjugated antibody
and goat anti-rabbit secondary antibodies conjugated to Horse
Radish Peroxidase (HRP) were from Sigma-Aldrich (St Louis,
MO). LPS E. coli 0111:B4 was from Sigma (St Louis, MO).
PEPTIDE ANALOGS PREPARATION
GHRH agonist, JI-34, was synthesized in the laboratory of A.V.S.
and is 80 times more potent in stimulating the GHRH-R than
GHRH (Izdebski et al., 1995). For preparation of the stock
solution, the agonist was dissolved in DMSO.
DEPLETION OF PKAα CATALYTIC SUBUNIT AND PKC-α IN HL-MVEC
HL-MVEC were treated with a pool of 3 target-specific 19–25
nt siRNAs designed to knock down either PKAα catalytic sub-
unit or PKC-α gene expression. These were obtained from Santa
Cruz Biotechnology, Inc. (Dallas, TX, USA). Also a non-specific,
non-targeting siRNA was ordered from the same manufacturer.
All siRNA’s were received in lyophilized form. HL-MVEC were
transfected at 70–80% confluence with 75 nM final concen-
tration of siRNA using siPORT™ Amine transfection reagent
(Ambion, Life Technologies, Grand Island, NY) and used for
further experiments at 48 h post transfection.
WESTERN BLOTTING PROCEDURE
Immediately after treatment, HL-MVEC were washed twice with
ice-cold PBS and lysed with lysis buffer [20mM Tris·HCl (pH
7.6), 0.5% Nonidet P-40, 250mM NaCl, 3mM EDTA, 3mM
EGTA, 1mM DTT, and protease inhibitor mixture]. The clear
supernatants after centrifugation were mixed with SDS sam-
ple buffer and boiled for 5min. Protein extracts were separated
on SDS/PAGE, transferred to a nitrocellulose membrane, incu-
bated with primary antibodies, and then incubated with HRP-
conjugated secondary antibody. The immunoreactive proteins
were visualized with LumiGLO solution (Cell Signaling, Danvers,
MA, USA) and were then exposed to X-ray film. The rela-
tive intensity of each protein band was quantified with ImageJ
software (National Institutes of Health).
MEASUREMENTS OF VE-CADHERIN EXPRESSION ZONE WIDTH
Analysis of VE cadherin zone expression was performed on
immunofluorescent images we prepared using primary rabbit
polyclonal anti-human VE-cadherin antibodies (Cell signaling,
Danvers, MA, USA) and secondary goat anti-rabbit Texas Red-
conjugated antibody (Sigma-Aldrich, St Louis, MO, USA) in
HPAECs, which are better suited for this type of measure-
ment than pulmonary microvascular endothelial cells. Images
were acquired using a N-SIM super-resolution system, assembled
on a TiE inverted microscope (Nikon, Japan) with a 100× oil
immersion lens (NA = 1.49) and an iXon-897 EMCCD-camera
(Andor, Ireland, effective pixel size 60 nm). Original images were
processed using ImageJ software (Gaussian filtration and back-
ground subtraction). Measurements of the width of VE-cadherin
expression zone were produced using ImageJ software (function
“Measure”). Statistical analysis was performed using Sigma Plot
7.1 (SPSS Science, Point Richmond, CA) and Excel. Sigma Plot
7.1 software was used for graphical data presentation.
MEASUREMENT OF TRANSENDOTHELIAL ELECTRICAL RESISTANCE
(TER)
TER in HL-MVEC monolayers [electrical cell-substrate
impedance sensing (ECIS) system 1600R; Applied Biophysics,
Troy, NY, USA] was measured as described previously (Lucas
et al., 2012a,b).
ASSESSMENT OF CAPILLARY LEAK IN VIVO
Mice (n = 10 per group), pretreated i.v. or not at −24 h and
at −1 h before toxin instillation with JI-34 (100μg/kg) were
anesthetized with i.p. ketamine (150mg/kg) and acetylpromazine
(15mg/kg). Subsequently the trachea was exposed and LPS
(Sigma-Aldrich, E. coli 0111:B4, 0.65mg/kg in saline) was instilled
i.t. for 24 h in anesthetized mice via a 20-gauge catheter. An Evans
Blue dye (EBD)/Albumin mixture (30mg/kg in saline; (0.5%
EBD conjugated to 4% BSA, Fraction V; Sigma-Aldrich, St Louis,
MO) was injected into the tail vein of 6 mice per group, 2 h
before mice were killed, in order to assess vascular leak. Lungs
free of blood were weighed and snap-frozen in liquid nitrogen.
The left lung was homogenized, incubated with formamide (18 h
at +60◦C), and centrifuged at 5000 × g for 30min. The optical
density of the supernatant was determined spectrophotometri-
cally at 620–750 nm. Extravasated EBD concentration in the lungs
was calculated by using a standard curve (μg of EBD per g of
wet lung tissue), as described previously (Lucas et al., 2012a,b).
For pro-inflammatory mediator determination, collected bron-
choalveolar lavage fluid (BALF) from another 4 mice per group
was centrifuged (500 × g for 15min at 4◦C), supernatant was
centrifuged again (5000 × g for 15min at 4◦C), and pure BALF
was used to measure cytokine/chemokine/growth factor con-
centrations using the multiplex MCYTOMAG-70K assay (EMD
Millipore, Billerica, MA, USA), according to the manufacturer’s
instructions.
STATISTICAL ANALYSIS
All experimental data are presented as mean ± SD. Control sam-
ples and those obtained upon various stimuli were compared
by unpaired Student’s t-test. For multiple group comparisons,
One-Way ANOVA was used. p < 0.05 was considered statistically
significant.
RESULTS
GHRH AGONIST PRESERVES VE-CADHERIN EXPRESSION IN
LPS-TREATED HUMAN ENDOTHELIAL MONOLAYERS IN VITRO
The main function of VE-cadherin, a crucial component of
endothelial adherens junctions, is the stabilization of endothe-
lial cell integrity. VE-cadherin expression was shown to be
significantly reduced in the endothelium of all vessel types
in the lungs of G−-sepsis-induced acute respiratory distress
syndrome (ARDS) or in endothelial cells treated with LPS
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(Herwig et al., 2013). As shown in Figures 1A,B, treatment of
monolayers of HPAECs for 6 h with LPS (500 ng/ml) leads to a
significant reduction in VE-cadherin expression, measured as the
mean of the VE-cadherin zone width (in μm). Pretreatment of
the monolayers for 15min with the GHRH agonist, JI-34 (1μM),
before LPS addition significantly blunted the effect of LPS and
increased VE-cadherin expression even in control cells. In view
of the crucial role of VE-cadherin expression for barrier func-
tion, these results indicate a barrier-protective effect of GHRH in
LPS-treated endothelial cells in vitro. Since LPS exerts both direct
and indirect (cytokine-mediated) deleterious actions on barrier
function in the lung in vivo, in the subsequent study we inves-
tigated whether JI-34 can also blunt LPS-induced capillary leak
in mice.
JI-34 BLUNTS LPS-INDUCED PULMONARY CAPILLARY LEAK IN VIVO
As shown in Figure 2, a combined i.v. pretreatment of 8 weeks
old male C57BL6 mice (n = 6), with JI-34 (100μg/kg) at 24 and
1 h prior to i.t. LPS instillation (0.65mg/kg) induced a signifi-
cant protection from LPS-induced capillary leak, as compared to
vehicle control and measured as EBD incorporation in the lung
tissue. As depicted in Figure 3, JI-34 did not affect the concentra-
tion of the pro-inflammatory cytokines TNF, IL-1β, and IL-6 or
of the anti-inflammatory cytokine IL-10 in BALF of LPS-treated
animals, as measured by multiplex analysis.
Moreover, neither the generation of the pro-inflammatory
leukocyte-attracting chemokinesMCP-1, MIP-1β, andMIP-2 nor
of the permeability-increasing factor, VEGF, were affected by the
GHRH agonist in LPS-instilled mice (Figure 4). These results
suggest that the barrier-protective effect of JI-34 in lungs of LPS-
treated mice results mainly from blunting direct, rather than
indirect, leukocyte-mediated effects of LPS.
CRUCIAL ROLE FOR PROTEIN KINASE A IN BARRIER-PROTECTIVE
ACTIVITY OF GHRH AGONISTS IN HUMAN LUNG MICROVASCULAR
ENDOTHELIAL CELLS
In endothelial cells, cAMP potentiates VE-cadherin-mediated
cell-cell contacts, causing enhanced endothelial barrier func-
tion (Dejana et al., 2008). The observed inhibitory activity of
the GHRH agonist, JI-34, on both PLY-mediated (Lucas et al.,
2012a) and LPS-induced VE-cadherin loss (Figures 1A,B), can
thus, at least partially, be explained by its capacity to activate
cAMP, upon activating the SV1 receptor, expressed in HL-MVEC.
cAMP can however activate both PKA and Epac. PKA exerts
its barrier-protective effects upon phosphorylating its substrates,
including VASP, which was shown to be important in protecting
endothelial barriers from LPS action (Bogatcheva et al., 2009). By
contrast, Epac activates the barrier protective Rap1/Rac 1 cascade
(Fukuhara et al., 2005).
FIGURE 2 | Evans Blue Dye incorporation in lung tissue in 8–10 weeks
old male C57BL6 mice (n = 6 per group) treated i.t. with 0.65mg/kg
LPS. Mice were pretreated either with vehicle (DMSO) or with JI-34
(100μg/kg) at 24 and 1 h before receiving LPS. Data are given as mean ±
SD (gray bars).
FIGURE 1 | Effect of LPS and JI-34 on VE-cadherin adherens junction of
human pulmonary artery endothelial cells (HPAEC). (A) Cells were
pretreated with JI-34 (1μM, 15min) or not, followed by LPS stimulation
(500 ng/ml, 6 h) and stained with VE-cadherin antibodies for VE-cadherin
adherens junction protein detection. (B) Measurements of VE-cadherin
expression zone width were carried out on immunofluorescent images using
ImageJ software. Mean of VE-cadherin zone width are presented as ± SD
(gray bars) (n = 100 for each experimental treatment).
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FIGURE 3 | Concentrations of (A) TNF; (B) IL-6; (C) IL-1β; and (D)
IL-10 in BALF from vehicle-treated, LPS-treated (0.65mg/kg) or
JI-34 (100μg/kg) + LPS treated mice (n = 4 per group) in pg/ml,
as assessed using the Multiplex MCYTOMAG-70K assay (EMD
Millipore, Billerica, MA, USA). Data are presented as mean ± SD
(gray bars).
FIGURE 4 | Concentrations of the chemokines (A) MCP-1; (B) MIP-1β;
(C) MIP-2; and the growth factor (D). VEGF in BALF from
vehicle-treated, LPS-treated or JI-34 + LPS treated mice (n = 4 per
group) in pg/ml, as assessed using the Multiplex MCYTOMAG-70K assay
(EMD Millipore, Billerica, MA, USA). Data are presented as mean ± SD
(gray bars).
Since agonists of both PKA and Epac can independently pro-
tect from LPS-induced hyperpermeability (Bogatcheva et al.,
2009), we investigated whether specific activation of Epac, using
the agonist 2′-O-Methyl-cAMP, can protect from PLY-mediated
barrier dysfunction. As shown in Figure 5, 2′-O-Methyl-cAMP
failed to restore barrier function in PLY-treated HL-MVEC, at
a concentration of 100μM, which was previously demonstrated
to protect from LPS-induced hyperpermeability in these cells
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FIGURE 5 | The Epac agonist 2′-O-Me-cAMP (100μM) does not prevent
PLY (30ng/ml)-mediated hyperpermeability, measured as normalized
transendothelial electric resistance (TER) in HL-MVEC (ECIS, n = 4,
6 h). Mean ± SD (gray bars).
(Bogatcheva et al., 2009). Since we have previously shown that
cAMP protects from PLY-mediated barrier dysfunction in mono-
layers of HL-MVEC (Umapathy et al., 2010), this result suggests
that the protective effect of the GHRH agonist JI-34 in PLY-
mediated barrier dysfunction is dependent on the activation of
PKA, rather than of Epac.
In order to substantiate this hypothesis, we investigated
whether JI-34 can activate PKA in the absence or presence of
LPS or PLY. As shown in Figure 6A, JI-34 (1μM) increases PKA
activity, assessed as the expression of PKA-phosphorylated sub-
strate protein in Western blotting in both resting and LPS-treated
HL-MVEC monolayers. Further, as shown in Figures 6B,C, JI-34
(1μM) also activates PKA in PLY (30 ng/ml)-treated HL-MVEC,
measured as the increased expression of phosphorylated over total
PKA. Taken together, these results indicate that the activation of
PKA, rather than of Epac, mediates the protective activity of JI-34
in both LPS- and PLY-mediated barrier dysfunction.
ACTIVATION OF SV-1 RECEPTOR IN HL-MVEC CAN STIMULATE
BACTERIAL TOXIN-INDUCED ACTIVATION OF PKC-α
GHRH is a member of the glucagon/secretin superfamily, the
members of which have the capacity to activate receptors coupled
with multiple heterotrimeric Gq proteins, which have the capac-
ity to increase intracellular Ca2+ (Mayo et al., 1995; Sherwood
et al., 2000). The Gαq subunit, which was reported to be activated
upon GHRH-R stimulation, has the capacity to activate PKC,
after first stimulating phospholipase C (PLC) (Lania et al., 2003).
In this study, we therefore investigated whether a 30min incu-
bation with JI-34 (1μM) of both resting cells and PLY-treated
cells can increase PKC activity, assessed as the expression of PKC-
phosphorylated protein substrate in Western Blotting. As shown
in Figure 7A, a 30min pretreatment of HL-MVEC monolayers
with JI-34 (1μM) increases the expression of protein substrates
phosphorylated by PKC in the presence of PLY (15 ng/ml), which
by itself activates this process within 15min. One of the most
important PKC isoforms which is activated in JI-34/PLY-treated
cells is PKC-α (Figure 7B, upper panel), since siRNA-mediated
PKC-α gene depletion significantly reduces JI-34/PLY-mediated
phosphorylation of PKC substrates in these cells (Figure 7B,
lower panel). Interestingly, as shown in Figures 8A,B, JI-34 did
FIGURE 6 | Representative Western blots of the PKA-activating activity
of a 30min JI-34 preincubation (1μM) in ctrl, LPS (2h, 200ng/ml)- or
PLY-(30min, 30ng/m) treated HL-MVEC. (A) Expression of PKA protein
substrates in LPS-treated or control cells, in the presence or absence of
JI-34; (B) Phospho-PKA and total PKA protein expression in control and
PLY-treated cells, in the presence or absence of JI-34. (C) Quantification of
phospho-PKA over total PKA ratio (n = 3 per group, mean ± SD).
not further increase LPS (1μg/ml)-induced PKC-α activation, in
contrast to what we observed in PLY-treated cells.
PKA GENE DEPLETION BLUNTS THE BARRIER-PROTECTIVE ACTIVITY
OF GHRH AGONIST IN PLY-TREATED HL-MVEC MONOLAYERS
In view of our previous observations that JI-34 treatment
can increase both barrier-protective PKA activity and barrier-
disruptive PKC-α signaling in the presence of PLY, we next
investigated the outcome of siRNA-mediated gene depletion of
the PKAα catalytic subunit, on the JI-34-induced PKC activation
in HL-MVEC monolayers. As shown in Figure 9, PKAα catalytic
site (cat) gene depletion significantly increases basal and JI-34-
induced PKC activity, measured as the expression of phosphory-
lated PKC protein substrates, as compared to scrambled siRNA
transfection.
As shown in Figure 10A, PKA gene depletion blunts the pro-
tective effect of JI-34 toward PLY (30 ng/ml), seen in scrambled
siRNA-treated cells. Monolayer resistance of untreated scram-
bled siRNA-treated HL-MVEC monolayers is not significantly
different from untreated control cells (data not shown). PKAα
cat siRNA-transfected cells display an increased sensitivity to
PLY (Figures 10A,B). The latter result is somewhat in contrast
with the equal total PKC activity detected in Western blotting
(Figure 9), but could represent an increased activation of barrier-
disruptive (such as PKC-α) over barrier-protective PKC isoforms
(such as PKC-δ) in HL-MVEC, which would not necessarily be
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FIGURE 7 | (A) Expression of PKC-phosphorylated protein substrates in
ctrl, PLY (30 ng/ml), JI-34 (1μM), and JI-34 + PLY-treated HL-MVEC. Cells
were pretreated for 30min with JI-34 and were then incubated for
15min with PLY. (B) Representative WB of the Influence of
siRNA-mediated PKC-α gene depletion on PLY- and JI-34 induced total
PKC activity in HL-MVEC.
FIGURE 8 | Representative Western Blot demonstrating (A)
phosphorylated PKC-α and total PKC-α activity in ctrl, LPS-treated
(1μg/ml, 1 h) and JI-34(1μM, 15min)/LPS-treated HL-MVEC. (B)
Phosphorylated over total PKC-α ratios. Mean + SD (gray bars) (n = 3 per
group).
FIGURE 9 | Representative WB of the influence of PKA-α catalytic
subunit siRNA-mediated gene depletion [depicted as siRNA (PKA)] on
basal, JI-34- (1 μM) and PLY- (30ng/ml) mediated total PKC activation,
assessed as phosphorylated PKC substrates.
detected in the total PKC activity. As shown in Figure 10B, at
a lower PLY concentration (15 ng/ml), the protective effect of
JI-34 may shift even to a deleterious one in PKA-gene depleted
cells.
FIGURE 10 | (A) TER of HL-MVEC monolayers transfected with either
scrambled (control) or PKAα cat. siRNA, that were treated with vehicle,
JI-34 (1μM), PLY (30 ng/ml), or JI-34 + PLY. N = 4 per group and data are
depicted as mean ± SD. (B) TER at 20 h of ctrl or PKA-depleted HL-MVEC
treated with JI-34 (1μM), PLY (15 ng/ml), or JI-34 + PLY. ∗p < 0.05 vs. ctrl;
#p < 0.05 vs. PLY in control siRNA-treated cells; #,&p < 0.05 vs. PLY in
siRNA (PKA) transfected cells.
DISCUSSION
Both the GHRH-R and the bioactive SV1 receptor, the latter of
which is expressed in HL-MVEC, are coupled to heterotrimeric
G proteins (Mayo et al., 1995; Sherwood et al., 2000; Kiaris
et al., 2011). The latter consist of α, β, and γ subunits and func-
tion as transducers of signals from G-protein coupled receptors
(GPCRs). Whereas the α subunit is the GTP binding protein,
the β and γ subunits are anchored to the plasma membrane
and bind the GDP-bound α subunit with high affinity to con-
stitute the heterotrimer. Although the barrier-protective roles
of cAMP and of PKA are well-documented (Bogatcheva et al.,
2009), the JI-34-induced interplay between the barrier-protective
PKA, induced upon GαS activation and the barrier-disruptive
PKC-α, activated by Gαq, represents a unique situation. This
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can be especially relevant in the presence of bacterial toxins,
such as PLY and LPS, which were both shown to activate PKC-α
(Witzenrath et al., 2006; Lucas et al., 2012b; Zhao et al., 2013).
Thus, unraveling the mechanism by which agonists of GHRH
exert their protective effect under these complex circumstances
is important. Pathways promoting hyperpermeability in PLY- or
LPS-treated MVEC include both MLC-dependent mechanisms
and microtubule de-polymerization, the latter of which can cause
disassembly of adherens junction proteins, such as VE-cadherin
(Petrache et al., 2003; Lucas et al., 2012a). By contrast, activa-
tion of PKA, by means of cAMP, was shown to stabilize barrier
function in the presence of LPS and PLY (Bogatcheva et al., 2009;
Umapathy et al., 2010).
We show in this study that the GHRH agonist JI-34 not
only protects HL-MVEC monolayers from PLY-induced barrier
dysfunction, but also from LPS-mediated impairment of VE cad-
herin expression. This adherens junction protein is a relevant
parameter of barrier function during acute lung injury. Indeed,
a significant reduction of VE cadherin expression was recently
detected in lung capillaries of patients with G− sepsis-induced
ARDS (Herwig et al., 2013). As such, the VE cadherin expression-
restoring activity of JI-34 can provide a plausible explanation
for the observed protection from capillary leak in mice which
have been instilled i.t. with LPS. Indeed, the improved barrier
function in GHRH agonist/LPS-treated animals is not a conse-
quence of a reduced inflammatory response, but rather of an
inhibition of direct effects of LPS on the integrity of the lung
capillaries. Our data have also shown that of the two pathways
induced by cAMP generation following GαS activation, Epac and
PKA, in particular the latter seems to be crucial for the protective
effect of the GHRH agonist in PLY-treated cells. Indeed, the Epac
agonist 2′-O-Me-cAMP failed to protect HL-MVEC monolay-
ers from PLY-mediated barrier dysfunction, in contrast to cAMP
(Umapathy et al., 2010) and siRNA-mediated depletion of PKA
completely blunted the protective effect of JI-34.
Activation of PKA has been demonstrated to attenuate both
epithelial and endothelial barrier dysfunction (Lawrence et al.,
2002; Fukuhara et al., 2005). In the endothelium, PKA activation
can blunt ROCK activity by direct phosphorylation of RhoGDI
and prevention of the release of RhoA from the RhoA-RhoGDI
complex (Qiao et al., 2008). Cyclic AMP potentiates VE-cadherin-
mediated cell-cell contacts, causing enhanced endothelial barrier
function (Dejana et al., 2008). Hence, our observed inhibitory
activity of GHRH agonist, JI-34, on PLY- and LPS-mediated VE-
cadherin loss can at least partially be explained by its capacity to
activate cAMP/PKA pathway, upon binding to the SV1 receptor,
expressed in HL-MVEC.
As demonstrated in this study, JI-34 treatment, beyond acti-
vating PKA in PLY-treated HL-MVEC, also further increases
PLY-induced activation of the PKC-α isoform of PKC. This
kinase mediates PLY-induced endothelial hyperpermeability,
upon stimulating the barrier disruptive RhoA/ROCK pathway,
which increases MLC phosphorylation, actomyosin contractility
and intercellular gap formation. Although JI-34 increases PLY-
induced PKC-α activity, it does not affect LPS-induced activation
of this enzyme. This could potentially be linked to the fact that
LPS increases several PKC isoforms, whereas PLY, which induces
a large influx of extracellular Ca2+ upon pore formation in HL-
MVEC, can preferentially activate Ca2+-dependent isoforms, of
which PKC-α is the main representative.
Although the stimulation of the SV1 receptor in HL-MVEC
induces two apparently opposing pathways in the presence of
PLY. On the one hand, GHRH agonist stimulates the barrier-
protective cAMP/PKA pathway and on the other hand it increases
the barrier-disruptive PKC-α/RhoA/ROCK pathway. Our results
demonstrate an overriding role for the PKA pathway over the
PKC-α pathway under these conditions. However, as shown in
Figures 10A,B, when the PKA pathway is impaired, the PKC path-
way prevails. Taken together, these results suggest that GHRH
agonists will protect from PLY-induced hyperpermeability pro-
vided the cAMP/PKA pathway is intact.
Lesions of specific anatomical sites in the brainstem and
hypothalamus may initiate acute pulmonary edema. This
occurrence has been termed neurogenic pulmonary edema.
Unfortunately, the pathophysiologic explanation of this response
is not clearly understood. Although hydrostatic derangements
may explain certain cases of neurogenic pulmonary edema, recent
clinical and experimental studies have indicated that central ner-
vous system disorders may cause a permeability defect without
a vascular insult (Colice et al., 1984). The mediating factor for
this permeability defect is not clear. It is therefore tempting to
hypothesize that peripheral actions of GHRH produced in the
hypothalamus may control pulmonary barrier integrity. When
this production is impaired, as may occur from brainstem lesions,
this may affect pulmonary barrier integrity.
Since GHRH agonists have a longer half-life than the native
hypothalamic GHRH hormone (Izdebski et al., 1995; Cai et al.,
2014), they can provide a more potent signal to damaged lungs
and could promote a change in the concept of treating pulmonary
edema. GHRH agonists could improve lung function in patholo-
gies associated with pulmonary permeability edema, such as CNS
trauma, ARDS, and severe pneumonia.
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